UA74807C2 - Rapid onset formulation for preventing nausea and vomiting, process for its manufacture and dosage form - Google Patents

Rapid onset formulation for preventing nausea and vomiting, process for its manufacture and dosage form Download PDF

Info

Publication number: UA74807C2
Authority: UA; Ukraine
Prior art keywords: composition; minutes; doxylamine succinate; dissolution; pyridoxine hci
Prior art date: 2000-12-20

Application number

UA2002065093A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Duchesnay Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-20

Filing date

2001-06-21

Publication date

2006-02-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42104724&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA74807(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-06-21 Application filed by Duchesnay Inc filed Critical Duchesnay Inc

2006-02-15 Publication of UA74807C2 publication Critical patent/UA74807C2/uk

Links

239000000203 mixture Substances 0.000 title abstract description 76
238000009472 formulation Methods 0.000 title abstract 3
206010047700 Vomiting Diseases 0.000 title description 7
238000000034 method Methods 0.000 title description 7
238000004519 manufacturing process Methods 0.000 title description 5
239000002552 dosage form Substances 0.000 title description 4
230000008569 process Effects 0.000 title description 3
238000004090 dissolution Methods 0.000 abstract description 29
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract description 20
KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 abstract description 17
229960005008 doxylamine succinate Drugs 0.000 abstract description 17
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract description 16
238000009505 enteric coating Methods 0.000 abstract description 10
239000002702 enteric coating Substances 0.000 abstract description 10
238000005259 measurement Methods 0.000 abstract description 9
239000000377 silicon dioxide Substances 0.000 abstract description 9
235000008160 pyridoxine Nutrition 0.000 abstract description 8
239000011677 pyridoxine Substances 0.000 abstract description 8
229940011671 vitamin b6 Drugs 0.000 abstract description 8
239000000945 filler Substances 0.000 abstract description 6
239000011230 binding agent Substances 0.000 abstract description 5
239000008363 phosphate buffer Substances 0.000 abstract description 5
239000000314 lubricant Substances 0.000 abstract description 4
239000000546 pharmaceutical excipient Substances 0.000 abstract description 4
239000003381 stabilizer Substances 0.000 abstract description 3
239000003795 chemical substances by application Substances 0.000 abstract 2
ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 16
229960004172 pyridoxine hydrochloride Drugs 0.000 description 16
235000019171 pyridoxine hydrochloride Nutrition 0.000 description 16
239000011764 pyridoxine hydrochloride Substances 0.000 description 16
239000004480 active ingredient Substances 0.000 description 15
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 9
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 9
229920002472 Starch Polymers 0.000 description 8
235000012239 silicon dioxide Nutrition 0.000 description 8
239000008107 starch Substances 0.000 description 8
229940032147 starch Drugs 0.000 description 8
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 7
229920000168 Microcrystalline cellulose Polymers 0.000 description 7
239000001913 cellulose Substances 0.000 description 7
239000003814 drug Substances 0.000 description 7
238000009499 grossing Methods 0.000 description 7
239000004615 ingredient Substances 0.000 description 7
239000011777 magnesium Substances 0.000 description 7
229910052749 magnesium Inorganic materials 0.000 description 7
229940016286 microcrystalline cellulose Drugs 0.000 description 7
235000019813 microcrystalline cellulose Nutrition 0.000 description 7
239000008108 microcrystalline cellulose Substances 0.000 description 7
235000019698 starch Nutrition 0.000 description 7
239000000126 substance Substances 0.000 description 7
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 6
235000010980 cellulose Nutrition 0.000 description 6
229920002678 cellulose Polymers 0.000 description 6
229920002785 Croscarmellose sodium Polymers 0.000 description 5
206010028813 Nausea Diseases 0.000 description 5
229960001681 croscarmellose sodium Drugs 0.000 description 5
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 5
GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 5
239000000391 magnesium silicate Substances 0.000 description 5
235000019793 magnesium trisilicate Nutrition 0.000 description 5
229940099273 magnesium trisilicate Drugs 0.000 description 5
229910000386 magnesium trisilicate Inorganic materials 0.000 description 5
230000008693 nausea Effects 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
229960005178 doxylamine Drugs 0.000 description 4
HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 4
229940079593 drug Drugs 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
210000002784 stomach Anatomy 0.000 description 4
230000008673 vomiting Effects 0.000 description 4
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
239000000783 alginic acid Substances 0.000 description 3
229960001126 alginic acid Drugs 0.000 description 3
150000004781 alginic acids Chemical class 0.000 description 3
239000012530 fluid Substances 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
239000006187 pill Substances 0.000 description 3
230000035935 pregnancy Effects 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
235000010413 sodium alginate Nutrition 0.000 description 3
239000000661 sodium alginate Substances 0.000 description 3
229940005550 sodium alginate Drugs 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
AAYNMUXDBOPKCP-UHFFFAOYSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;butanedioic acid;n,n-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine;hydron;chloride Chemical compound Cl.OC(=O)CCC(O)=O.CC1=NC=C(CO)C(CO)=C1O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 AAYNMUXDBOPKCP-UHFFFAOYSA-N 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 2
235000014698 Brassica juncea var multisecta Nutrition 0.000 description 2
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
239000000205 acacia gum Substances 0.000 description 2
244000275904 brauner Senf Species 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
229940075614 colloidal silicon dioxide Drugs 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
230000035943 smell Effects 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
239000004299 sodium benzoate Substances 0.000 description 2
235000010234 sodium benzoate Nutrition 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
230000009747 swallowing Effects 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
229920000856 Amylose Polymers 0.000 description 1
235000003097 Artemisia absinthium Nutrition 0.000 description 1
240000001851 Artemisia dracunculus Species 0.000 description 1
235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
235000003261 Artemisia vulgaris Nutrition 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
VFVKJZBVVLVXSP-UHFFFAOYSA-M C(CCCCCCCCCCCCCCCCC)(=O)[O-].OCCC[Mg+] Chemical compound C(CCCCCCCCCCCCCCCCC)(=O)[O-].OCCC[Mg+] VFVKJZBVVLVXSP-UHFFFAOYSA-M 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
235000008733 Citrus aurantifolia Nutrition 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
241000282412 Homo Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
201000010538 Lactose Intolerance Diseases 0.000 description 1
102000006835 Lamins Human genes 0.000 description 1
108010047294 Lamins Proteins 0.000 description 1
229920002774 Maltodextrin Polymers 0.000 description 1
239000005913 Maltodextrin Substances 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
235000000857 Pentadesma butyracea Nutrition 0.000 description 1
240000002134 Pentadesma butyracea Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
241000022563 Rema Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
235000011941 Tilia x europaea Nutrition 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
229920002494 Zein Polymers 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
HZVVJJIYJKGMFL-UHFFFAOYSA-N almasilate Chemical compound O.[Mg+2].[Al+3].[Al+3].O[Si](O)=O.O[Si](O)=O HZVVJJIYJKGMFL-UHFFFAOYSA-N 0.000 description 1
239000001138 artemisia absinthium Substances 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
235000010338 boric acid Nutrition 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
235000019519 canola oil Nutrition 0.000 description 1
239000000828 canola oil Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000002131 composite material Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
210000004268 dentin Anatomy 0.000 description 1
229940096516 dextrates Drugs 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
238000010586 diagram Methods 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229940069417 doxy Drugs 0.000 description 1
HALQELOKLVRWRI-VDBOFHIQSA-N doxycycline hyclate Chemical group O.[Cl-].[Cl-].CCO.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O HALQELOKLVRWRI-VDBOFHIQSA-N 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
239000008103 glucose Substances 0.000 description 1
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
229940046813 glyceryl palmitostearate Drugs 0.000 description 1
239000008187 granular material Substances 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
229960002003 hydrochlorothiazide Drugs 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
239000010977 jade Substances 0.000 description 1
210000005053 lamin Anatomy 0.000 description 1
239000004571 lime Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000001050 lubricating effect Effects 0.000 description 1
229940035034 maltodextrin Drugs 0.000 description 1
239000000463 material Substances 0.000 description 1
239000000155 melt Substances 0.000 description 1
150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
235000019814 powdered cellulose Nutrition 0.000 description 1
229920003124 powdered cellulose Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
239000000770 propane-1,2-diol alginate Substances 0.000 description 1
239000008213 purified water Substances 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
230000008786 sensory perception of smell Effects 0.000 description 1
239000011257 shell material Substances 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
OKODKVMXHLUQSW-JITBQSAISA-M sodium;(e)-4-hydroxy-4-oxobut-2-enoate;octadecanoic acid Chemical compound [Na+].OC(=O)\C=C\C([O-])=O.CCCCCCCCCCCCCCCCCC(O)=O OKODKVMXHLUQSW-JITBQSAISA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000011282 treatment Methods 0.000 description 1
239000001993 wax Substances 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1
239000005019 zein Substances 0.000 description 1
229940093612 zein Drugs 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Lubricants (AREA)
Seal Device For Vehicle (AREA)
Memory System Of A Hierarchy Structure (AREA)
Power Steering Mechanism (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

UA2002065093A 2000-12-20 2001-06-21 Rapid onset formulation for preventing nausea and vomiting, process for its manufacture and dosage form UA74807C2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CA002350195A CA2350195C (en)	2000-12-20	2000-12-20	Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate
US09/885,051 US6340695B1 (en)	2000-12-20	2001-06-21	Rapid onset formulation
PCT/CA2001/000951 WO2003000263A1 (en)	2000-12-20	2001-06-21	Rapid onset formulation

Publications (1)

Publication Number	Publication Date
UA74807C2 true UA74807C2 (en)	2006-02-15

Family

ID=42104724

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2002065093A UA74807C2 (en)	2000-12-20	2001-06-21	Rapid onset formulation for preventing nausea and vomiting, process for its manufacture and dosage form

Country Status (34)

Country	Link
US (1)	US6340695B1 (da)
EP (1)	EP1397133B1 (da)
JP (1)	JP4242763B2 (da)
KR (1)	KR100527985B1 (da)
CN (1)	CN1229112C (da)
AT (1)	ATE307582T1 (da)
AU (1)	AU2001272243B2 (da)
BE (1)	BE1014929A4 (da)
BR (1)	BR0107371A (da)
CA (1)	CA2350195C (da)
DE (2)	DE10196426T1 (da)
DK (2)	DK1397133T3 (da)
EG (1)	EG24483A (da)
ES (1)	ES2251494T3 (da)
FI (1)	FI117961B (da)
FR (1)	FR2826277B1 (da)
GB (1)	GB2383751C (da)
GR (1)	GR1004371B (da)
HU (1)	HU227003B1 (da)
IL (1)	IL150349A0 (da)
IS (1)	IS2225B (da)
IT (1)	ITTO20020524A1 (da)
LU (1)	LU90934B1 (da)
MC (1)	MC200059A1 (da)
MX (1)	MXPA02006037A (da)
MY (1)	MY132786A (da)
NL (1)	NL1020895C2 (da)
NO (1)	NO332190B1 (da)
PL (1)	PL204507B1 (da)
SE (1)	SE526307C2 (da)
TR (1)	TR200201685T1 (da)
UA (1)	UA74807C2 (da)
UY (1)	UY27352A1 (da)
WO (1)	WO2003000263A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2350195C (en) *	2000-12-20	2003-06-10	Duchesnay Inc.	Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate
US8012506B2 (en) *	2001-04-10	2011-09-06	Pernix Therapeutics, Llc	Tannate compositions, methods of making and methods of use
US8257746B2 (en)	2001-04-10	2012-09-04	Pernix Therapeutics, Llc	Tannate compositions, methods of making and methods of use
ES2229876B1 (es) *	2001-06-26	2006-03-01	Duchesnay Inc.	Formulacion de accion rapida.
CA2392486A1 (en) *	2002-07-05	2002-12-08	Duchesnay Inc.	Pharmaceutical dosage form bearing pregnancy-friendly indicia
CA2406592C (en) *	2002-10-04	2003-09-30	Duchesnay Inc.	Method of preparing pharmaceutical dosage forms containing multiple active ingredients
JP2004231520A (ja) *	2003-01-28	2004-08-19	Nichiko Pharmaceutical Co Ltd	保存安定性及び溶出速度に優れた医薬組成物
US20050004181A1 (en) *	2003-07-03	2005-01-06	Duchesnay Inc.	Use of anti-emetic for pre and post operative care
CA103771S (en)	2003-07-22	2006-01-18	Duchesnay Inc	Pharmaceutical dosage form
US20060280789A1 (en) *	2004-12-27	2006-12-14	Eisai Research Institute	Sustained release formulations
US20070129402A1 (en) *	2004-12-27	2007-06-07	Eisai Research Institute	Sustained release formulations
US20090208579A1 (en) *	2004-12-27	2009-08-20	Eisai R & D Management Co., Ltd.	Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
CA2592605C (en) *	2004-12-27	2010-12-07	Eisai R&D Management Co., Ltd.	Method for stabilizing anti-dementia drug
CA2604617C (en) *	2005-04-28	2014-06-17	Eisai R&D Management Co., Ltd.	Composition containing anti-dementia drug
US20070277530A1 (en) *	2006-05-31	2007-12-06	Constantin Alexandru Dinu	Inlet flow conditioner for gas turbine engine fuel nozzle
CN102108059B (zh) *	2010-09-03	2012-05-09	合肥工业大学	一种琥珀酸多西拉敏的合成方法
US8950188B2 (en)	2011-09-09	2015-02-10	General Electric Company	Turning guide for combustion fuel nozzle in gas turbine and method to turn fuel flow entering combustion chamber
WO2013123569A1 (en) *	2012-02-22	2013-08-29	Duchesnay Inc.	Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
JP5914701B2 (ja)	2012-02-22	2016-05-11	デュシネイ・インコーポレイテッド	ドキシラミンおよびピリドキシン、ならびに／またはその代謝物もしくは塩の製剤
JP5818219B2 (ja)	2012-05-14	2015-11-18	塩野義製薬株式会社	６，７−不飽和−７−カルバモイルモルヒナン誘導体含有製剤
PL3024466T3 (pl) *	2013-07-22	2018-08-31	Duchesnay Inc.	Kompozycja do kontrolowania nudności i wymiotów
CN103432126A (zh) *	2013-08-05	2013-12-11	北京阜康仁生物制药科技有限公司	一种治疗孕吐的药物组合物
SG11201701448XA (en) *	2014-08-29	2017-03-30	Duchesnay Inc	Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
US9526703B2 (en)	2014-08-29	2016-12-27	Duchesnay Inc.	Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
EP3337480A4 (en)	2015-08-17	2019-05-08	Aequus Pharmaceuticals Inc.	TRANSDERMAL ADMINISTRATION OF DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE
CN105510512B (zh) *	2016-01-25	2018-06-29	南京济群医药科技股份有限公司	一种琥珀酸多西拉敏有关物质的rt-hplc检测方法
RS61368B1 (sr) *	2018-09-27	2021-02-26	Inibsa Ginecologia S A	Postupak za pripremu višejediničnog oralnog doznog oblika sa modifikovanim oslobađanjem doksilamin sukcinata i piridoksin hidrohlorida
CN114099450A (zh) *	2020-08-31	2022-03-01	长春海悦药业股份有限公司	一种比拉斯汀片及其制备方法
AU2021225255B1 (en) *	2021-09-03	2022-06-16	Patel, Mihir MR	Compositions, kits, and methods to provide synergistic and/or additive effects from comprised ingredients for the prevention, treatment and management of nausea and vomiting.
CN118638044A (zh) *	2023-03-13	2024-09-13	南京济群医药科技股份有限公司	一种快速释放的琥珀酸多西拉敏组合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2085641A1 (en) *	1970-04-20	1971-12-31	Investigations Sci Pharm	Noramidopyrine doxylamine succinate compsn - antiinflammatories analgesics and antipyretics
US4642231A (en) *	1983-07-20	1987-02-10	Warner-Lambert Company	Magnesium trisilicate suitable for preparation of medicament adsorbates of antihistamines
CA2117351C (en) *	1992-01-13	1998-03-03	Julian Belknap Lo	Preparation of tablets of increased strength
CA2139896C (en) *	1995-01-10	2000-03-28	Don B. Mcdonah	Use of antinauseant agent for terminally ill humans
US6013280A (en) *	1997-10-07	2000-01-11	Fuisz Technologies Ltd.	Immediate release dosage forms containing microspheres
JP2003509439A (ja) *	1999-09-14	2003-03-11	スミスクライン・ビーチャム・コーポレイション	水性コーティングされたビーズレットの製法
CA2350195C (en) *	2000-12-20	2003-06-10	Duchesnay Inc.	Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate

2000
- 2000-12-20 CA CA002350195A patent/CA2350195C/en not_active Expired - Lifetime
2001
- 2001-06-21 DE DE10196426T patent/DE10196426T1/de not_active Ceased
- 2001-06-21 JP JP2003506908A patent/JP4242763B2/ja not_active Expired - Fee Related
- 2001-06-21 HU HU0301950A patent/HU227003B1/hu unknown
- 2001-06-21 US US09/885,051 patent/US6340695B1/en not_active Expired - Lifetime
- 2001-06-21 DE DE60114475T patent/DE60114475T2/de not_active Expired - Lifetime
- 2001-06-21 KR KR10-2002-7009679A patent/KR100527985B1/ko not_active Expired - Lifetime
- 2001-06-21 IL IL15034901A patent/IL150349A0/xx active IP Right Grant
- 2001-06-21 GB GB0213990A patent/GB2383751C/en not_active Expired - Lifetime
- 2001-06-21 UA UA2002065093A patent/UA74807C2/uk unknown
- 2001-06-21 CN CNB018145485A patent/CN1229112C/zh not_active Expired - Fee Related
- 2001-06-21 DK DK01951259T patent/DK1397133T3/da active
- 2001-06-21 ES ES01951259T patent/ES2251494T3/es not_active Expired - Lifetime
- 2001-06-21 WO PCT/CA2001/000951 patent/WO2003000263A1/en not_active Ceased
- 2001-06-21 TR TR2002/01685T patent/TR200201685T1/xx unknown
- 2001-06-21 AU AU2001272243A patent/AU2001272243B2/en not_active Expired
- 2001-06-21 BR BR0107371-0A patent/BR0107371A/pt not_active Application Discontinuation
- 2001-06-21 MX MXPA02006037A patent/MXPA02006037A/es active IP Right Grant
- 2001-06-21 AT AT01951259T patent/ATE307582T1/de active
- 2001-06-21 PL PL362763A patent/PL204507B1/pl unknown
- 2001-06-21 EP EP01951259A patent/EP1397133B1/en not_active Expired - Lifetime
2002
- 2002-06-07 IS IS6412A patent/IS2225B/is unknown
- 2002-06-12 GR GR20020100280A patent/GR1004371B/el unknown
- 2002-06-18 NL NL1020895A patent/NL1020895C2/nl not_active IP Right Cessation
- 2002-06-18 IT IT2002TO000524A patent/ITTO20020524A1/it unknown
- 2002-06-19 EG EG2002060693A patent/EG24483A/xx active
- 2002-06-19 MY MYPI20022296A patent/MY132786A/en unknown
- 2002-06-20 MC MC2486A patent/MC200059A1/fr unknown
- 2002-06-20 FR FR0207643A patent/FR2826277B1/fr not_active Expired - Lifetime
- 2002-06-20 NO NO20022982A patent/NO332190B1/no not_active IP Right Cessation
- 2002-06-20 BE BE2002/0397A patent/BE1014929A4/fr not_active IP Right Cessation
- 2002-06-20 DK DK200200947A patent/DK176018B1/da not_active IP Right Cessation
- 2002-06-21 LU LU90934A patent/LU90934B1/fr active
- 2002-06-21 UY UY27352A patent/UY27352A1/es not_active Application Discontinuation
- 2002-07-03 SE SE0202061A patent/SE526307C2/sv unknown
- 2002-09-25 FI FI20021708A patent/FI117961B/fi not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE60114475D1 (de)	2005-12-01
MY132786A (en)	2007-10-31
NL1020895C2 (nl)	2003-03-13
MXPA02006037A (es)	2005-05-12
AU2001272243B2 (en)	2004-02-05
NO20022982D0 (no)	2002-06-20
IS6412A (is)	2002-12-22
HU227003B1 (en)	2010-04-28
FR2826277A1 (fr)	2002-12-27
DK176018B1 (da)	2005-12-05
BE1014929A4 (fr)	2004-06-01
FI20021708A0 (fi)	2002-09-25
FI117961B (fi)	2007-05-15
SE0202061L (sv)	2003-01-28
IL150349A0 (en)	2003-12-23
GB2383751A (en)	2003-07-09
GB2383751C (en)	2008-08-05
EP1397133B1 (en)	2005-10-26
HUP0301950A3 (en)	2005-06-28
GR20020100280A (el)	2003-03-28
CN1447694A (zh)	2003-10-08
IS2225B (is)	2007-04-15
DK200200947A (da)	2003-01-03
ATE307582T1 (de)	2005-11-15
ITTO20020524A1 (it)	2003-12-18
KR100527985B1 (ko)	2005-11-09
NO20022982L (no)	2002-10-09
NO332190B1 (no)	2012-07-23
CN1229112C (zh)	2005-11-30
ES2251494T3 (es)	2006-05-01
SE526307C2 (sv)	2005-08-16
TR200201685T1 (tr)	2003-06-23
FI20021708L (fi)	2002-12-22
NL1020895A1 (nl)	2002-12-30
UY27352A1 (es)	2002-09-30
CA2350195A1 (en)	2001-08-11
US6340695B1 (en)	2002-01-22
LU90934B1 (fr)	2002-12-23
KR20030023612A (ko)	2003-03-19
PL362763A1 (en)	2004-11-02
GR1004371B (el)	2003-10-23
DE60114475T2 (de)	2006-07-13
HK1052654A1 (en)	2003-09-26
GB0213990D0 (en)	2002-07-31
DK1397133T3 (da)	2006-02-27
ITTO20020524A0 (it)	2002-06-18
MC200059A1 (fr)	2003-01-30
JP2004521146A (ja)	2004-07-15
PL204507B1 (pl)	2010-01-29
DE10196426T1 (de)	2003-08-21
HUP0301950A2 (hu)	2003-11-28
JP4242763B2 (ja)	2009-03-25
CA2350195C (en)	2003-06-10
EG24483A (en)	2009-08-09
EP1397133A1 (en)	2004-03-17
FR2826277B1 (fr)	2004-07-02
SE0202061D0 (sv)	2002-07-03
WO2003000263A1 (en)	2003-01-03
IE20020488A1 (en)	2003-04-30
GB2383751B (en)	2005-02-09
BR0107371A (pt)	2003-06-10

Publication	Publication Date	Title
KR100645866B1 (ko)	2006-11-15	발데콕시브 조성물
US6340695B1 (en)	2002-01-22	Rapid onset formulation
CN101257800B (zh)	2012-07-18	包含法莫替丁和布洛芬的药物
PL200957B1 (pl)	2009-02-27	Kompozycja farmaceutyczna celecoxib'u i zastosowanie kompozycji farmaceutycznej
AU2009349125B2 (en)	2016-05-19	Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
JPH08333253A (ja)	1996-12-17	イルベサルタン含有医薬組成物
JPS6124516A (ja)	1986-02-03	持続性錠剤
JP2020063292A (ja)	2020-04-23	ランタン化合物を含むカプセル製剤及び粉末製剤
AU2001272243A1 (en)	2003-06-19	Rapid onset formulation
TW508242B (en)	2002-11-01	Pharmaceutical composition comprising paracetamol
US20120003314A1 (en)	2012-01-05	Delayed-release oral pharmaceutical composition for treatment of colonic disorders
JP2014193878A (ja)	2014-10-09	トラネキサム酸製剤
JP2002326927A (ja)	2002-11-15	塩酸メトホルミン含有速放性錠剤
JPH1036269A (ja)	1998-02-10	月経困難症及び／又は月経前症候群の軽減用薬剤
CN114173767A (zh)	2022-03-11	布洛芬和对乙酰氨基酚的新型组合物
JP6461186B2 (ja)	2019-01-30	悪心、嘔吐または下痢の症状を処置するためのオンダンセトロン徐放固形製剤
WO1993005770A1 (fr)	1993-04-01	Preparation a longue duree d'action
ZA200603421B (en)	2007-09-26	A controlled release pharmaceutical composition and a process for preparing the same
CA2761795C (en)	2017-02-21	Burst drug release compositions
AU637782B2 (en)	1993-06-10	An erosion-controlled release system for active agents and a process for its preparation
RU2266744C2 (ru)	2005-12-27	Композиция быстрого начала действия
TW202615019A (zh)	2026-04-16	Glp-1r激動劑與恩格列淨的藥物組合物及用途
US20200297642A1 (en)	2020-09-24	Burst drug release compositions
AU2014201094B2 (en)	2016-06-30	Burst drug release compositions
AU2007201830B2 (en)	2009-11-12	High drug load tablet